Viracta Therapeutics (NASDAQ:VIRX) Stock Rating Reaffirmed by Oppenheimer

Viracta Therapeutics (NASDAQ:VIRX)‘s stock had its “outperform” rating reaffirmed by equities research analysts at Oppenheimer in a research note issued on Wednesday, Benzinga reports. They presently have a $13.00 price objective on the stock.

Separately, HC Wainwright reissued a “buy” rating and set a $4.00 target price on shares of Viracta Therapeutics in a research report on Tuesday.

Viracta Therapeutics Stock Performance

Shares of NASDAQ:VIRX traded up $0.22 during midday trading on Wednesday, hitting $0.94. The company’s stock had a trading volume of 190,591 shares, compared to its average volume of 113,969. Viracta Therapeutics has a fifty-two week low of $0.43 and a fifty-two week high of $2.38. The stock has a market capitalization of $36.77 million, a price-to-earnings ratio of -0.68 and a beta of 0.93. The stock’s 50 day simple moving average is $0.89 and its 200 day simple moving average is $0.70.

Viracta Therapeutics (NASDAQ:VIRX) last released its earnings results on Thursday, March 7th. The company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.05). As a group, analysts anticipate that Viracta Therapeutics will post -1.28 EPS for the current year.

Institutional Investors Weigh In On Viracta Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC boosted its holdings in Viracta Therapeutics by 94.6% during the second quarter. Renaissance Technologies LLC now owns 93,399 shares of the company’s stock valued at $362,000 after purchasing an additional 45,399 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Viracta Therapeutics by 3.0% during the fourth quarter. Geode Capital Management LLC now owns 224,438 shares of the company’s stock valued at $327,000 after purchasing an additional 6,502 shares in the last quarter. Millennium Management LLC boosted its holdings in Viracta Therapeutics by 32.3% during the fourth quarter. Millennium Management LLC now owns 198,904 shares of the company’s stock valued at $290,000 after purchasing an additional 48,530 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in Viracta Therapeutics by 22.7% during the fourth quarter. Dimensional Fund Advisors LP now owns 179,621 shares of the company’s stock valued at $263,000 after purchasing an additional 33,290 shares in the last quarter. Finally, Cubist Systematic Strategies LLC boosted its holdings in Viracta Therapeutics by 65.5% during the third quarter. Cubist Systematic Strategies LLC now owns 22,371 shares of the company’s stock valued at $96,000 after purchasing an additional 8,854 shares in the last quarter. 31.37% of the stock is owned by institutional investors and hedge funds.

About Viracta Therapeutics

Viracta Therapeutics, Inc, a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir.